Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of TNX-102 SL vs AMRIX in Healthy Subjects
NCT03443960Phase 1Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Tonmya in post-traumatic stress disorder (PTSD), fibromyalgia (FM) and Alzheimer's disease (AD) (2 arms), sponsored by Tonix Pharmaceuticals. Primary endpoints: Steady-State Area Under the Plasma Concentration Versus Time Curve, Peak Steady-State Plasma Concentration and 2 more. Started Jan 2018; status: completed.
02
Drugs
Tonmya
03
Conditions
post-traumatic stress disorder (PTSD)fibromyalgia (FM)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03443960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443960.